Last C$0.09 CAD
Change Today 0.00 / 0.00%
Volume 3.6K
MBI On Other Exchanges
As of 3:06 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

med biogene inc (MBI) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/8/13 - C$0.17
52 Week Low
06/3/14 - C$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MED BIOGENE INC (MBI)

Related News

No related news articles were found.

med biogene inc (MBI) Related Businessweek News

No Related Businessweek News Found

med biogene inc (MBI) Details

Med BioGene Inc., a life science company, focuses on managing the license and rights to the genomic-based clinical laboratory diagnostic tests. Its products include the GeneFx Lung, a gene expression-based test for early-stage non-small-cell lung cancer that analyzes the molecular profile of a patient’s tumor to provide information to assist in tailoring treatment for that specific patient. The company has a collaboration agreement with the University Health Network. Med BioGene Inc. was founded in 2002 and is headquartered in Vancouver, Canada.

Founded in 2002

med biogene inc (MBI) Top Compensated Officers

Executive Chairman and Member of Audit Commit...
Total Annual Compensation: $130.4K
Chief Financial Officer
Total Annual Compensation: $40.5K
Compensation as of Fiscal Year 2012.

med biogene inc (MBI) Key Developments

Med BioGene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014

Med BioGene Inc. reported earnings results for the first quarter ended March 31, 2014. During the three months ended March 31, 2014, net loss was $72,821 against $78,414 a year ago.

Med BioGene Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Med BioGene Inc. reported earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported loss of $67,320 or $0.00 per share compared to $66,239 a year ago. For the year, the company recorded a net loss of $759,288 compared to $368,083 a year ago. Cash used in operating activities was $398,294 compared to $329,549 for the year ended December 31, 2012.

Med BioGene Inc. Auditor Raises 'Going Concern' Doubt

Med BioGene Inc. filed its Annual on Apr 30, 2014 for the period ending Dec 31, 2013. In this report its auditor, De Visser Gray, gave an unqualified opinion expressing doubt that the company can continue as a going concern.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MBI:CN C$0.09 CAD 0.00

MBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MBI.
View Industry Companies

Industry Analysis


Industry Average

Valuation MBI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 163.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MED BIOGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at